Get the Stockscreener App
5.81
1.19%
-0.07
Aldeyra Therapeutics Inc stock is traded at $5.81, with a volume of 1.03M.
It is down -1.19% in the last 24 hours and up +8.40% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$5.88
Open:
$5.89
24h Volume:
1.03M
Relative Volume:
1.02
Market Cap:
$347.99M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-7.7467
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
+7.79%
1M Performance:
+8.40%
6M Performance:
-13.15%
1Y Performance:
+11.09%
1-Day Range:
$5.66
$6.05
1-Week Range:
$5.34
$6.05
52-Week Range:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.81 | 326.65M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Published on: 2025-08-21 07:52:25 - thegnnews.com
Don't Ignore The Insider Selling In Aldeyra Therapeutics - simplywall.st
Top Stocks to Watch: IOVA Surges on Regulatory Approval, FDA Fast Tracks Aldeyra Drug. - AInvest
Top Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra's Drug - RTTNews
Aldeyra Therapeutics Gains FDA Fast Track for ADX-2191 - TipRanks
FDA grants fast track designation for Aldeyra’s eye disease drug - Investing.com
Potential Breakthrough for 1M+ Patients: Aldeyra's Eye Drug Fast-Tracked for Untreated Blindness Condition - Stock Titan
Is This the Dip to Buy in Aldeyra Therapeutics Inc.Trade Analysis Report & Real-Time Buy Signal Notifications - newsyoung.net
Aldeyra Therapeutics Insider Buys Stock Amid Regulatory Progress - AInvest
Is Aldeyra Therapeutics Inc. part of any ETF2025 Trade Ideas & Short-Term Trading Opportunity Alerts - 선데이타임즈
Does Aldeyra Therapeutics Inc. fit your quant trading modelRate Cut & Weekly Chart Analysis and Trade Guides - Newser
Is Aldeyra Therapeutics Inc. forming a bottoming baseWeekly Market Summary & Safe Entry Zone Identification - Newser
Aldeyra Therapeutics Inc. stock trendline breakdownWeekly Trend Summary & AI Powered Market Trend Analysis - Newser
Published on: 2025-08-17 02:23:20 - 선데이타임즈
Comparing Aldeyra Therapeutics Inc. in custom built stock radarsWeekly Trade Review & Long-Term Capital Growth Ideas - Newser
What high frequency data says about Aldeyra Therapeutics Inc.July 2025 PostEarnings & Pattern Based Trade Signal System - Newser
Is Aldeyra Therapeutics Inc. building a consolidation base2025 Macro Impact & Free Daily Entry Point Trade Alerts - Newser
Aldeyra Therapeutics Sees Insider Confidence with New Stock Purchase! - TipRanks
What makes Aldeyra Therapeutics Inc. stock attractive to long term investorsWeekly Profit Analysis & Reliable Volume Spike Alerts - Newser
Can Aldeyra Therapeutics Inc. expand its profit marginsJuly 2025 Sentiment & Real-Time Volume Trigger Notifications - thegnnews.com
XTX Topco Ltd Acquires New Holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Defense World
Leerink Partnrs Issues Optimistic Forecast for ALDX Earnings - Defense World
Quantitative breakdown of Aldeyra Therapeutics Inc. recent moveJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - Newser
Aldeyra Therapeutics Inc. Ranks High in Smart Money TrackerWeekly Trade Analysis & Real-Time Chart Pattern Alerts - thegnnews.com
Is Aldeyra Therapeutics Inc. stock a top performer YTDQuarterly Portfolio Review & Fast Momentum Stock Entry Tips - thegnnews.com
HC Wainwright Issues Optimistic Estimate for ALDX Earnings - Defense World
HC Wainwright Has Pessimistic Outlook of ALDX Q3 Earnings - Defense World
Aldeyra therapeutics CDO sells $113k in shares By Investing.com - Investing.com Australia
Aldeyra therapeutics CDO sells $113k in shares - Investing.com
Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionAI Swing Strategy Signal Forecasting System - Newser
Buy Rating for Aldeyra Therapeutics Driven by FDA Progress and Strategic Partnership Potential - TipRanks
Aldeyra Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Aldeyra price target raised to $9 from $6 at Jones Trading on FDA acceptance - Investing.com Canada
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th A - GuruFocus
Aldeyra CEO to Share Exclusive Ophthalmology Pipeline Updates at H.C. Wainwright Conference - Stock Titan
Aldeyra Therapeutics (ALDX) Projected to Post Quarterly Earnings on Thursday - Defense World
AI Indicators Detect Buy Opportunity in Aldeyra Therapeutics Inc.Real-Time Analysis With Entry Targets In Progress - beatles.ru
Why is Aldeyra Therapeutics Inc. stock attracting strong analyst attentionTremendous portfolio expansion - Jammu Links News
Is Aldeyra Therapeutics Inc. a good long term investmentBuild a portfolio that outperforms the market - Jammu Links News
What makes Aldeyra Therapeutics Inc. stock price move sharplyFree Trend-Following Techniques - Jammu Links News
How does Aldeyra Therapeutics Inc. generate profit in a changing economyPowerful profit generation - Jammu Links News
Analyzing Aldeyra Therapeutics Inc. with risk reward ratio chartsDaily Market Momentum and Pressure Analysis - Newser
Should I hold or sell Aldeyra Therapeutics Inc. stock in 2025Strongest growth potential - Jammu Links News
When is Aldeyra Therapeutics Inc. stock expected to show significant growthSky-high profits - Jammu Links News
Published on: 2025-08-02 20:17:22 - beatles.ru
Is Aldeyra Therapeutics Inc. stock overvalued or undervaluedEarnings Report Alerts With Proven Results - Jammu Links News
What are analysts’ price targets for Aldeyra Therapeutics Inc. in the next 12 monthsWealth Building Insights That Work - Jammu Links News
How many analysts rate Aldeyra Therapeutics Inc. as a “Buy”AI Powered Entry Points That Work - Jammu Links News
Exploring US High Growth Tech Stocks For July 2025 - simplywall.st
Published on: 2025-07-29 20:51:08 - metal.it
Trendline Breach Raises Concern for Aldeyra Therapeutics Inc. InvestorsCommunity Verified Stock Suggestions Drive Volume - metal.it
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aldeyra Therapeutics Inc Stock (ALDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Machatha Stephen | Chief Development Officer |
Aug 11 '25 |
Sale |
5.15 |
22,073 |
113,713 |
221,799 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):